Myeloma therapy has undergone significant advances in recent years resulting in a marked improvement in survival. Knowledge of the active pathways involved in myeloma pathogenesis has led to the discovery of novel agents and greatly expanded the potential armamentarium available for treatment. This better understanding of the disease and resistance mechanisms has resulted in new agent classes that are being evaluated in preclinical and early clinical studies. In addition, dosing for existing agents is being optimized, and they are being given in new combinations. In this article, we review experimental agents that are showing promise in multiple myeloma treatment. New biological agents in clinical trials hold the promise of efficacy through novel mechanisms of action, with a significant reduction of dose-limiting toxicities compared with classic cytotoxic chemotherapeutics. Secondgeneration proteasome inhibitors and immunomodulatory agents are furthest along in clinical development, and histone deacetylase inhibitors, heat shock protein 90 inhibitors, Akt inhibitors and monoclonal antibodies are some of the other agents entering later-phase clinical trials. We also review developments in targeting the myeloma stem cell as an exciting new treatment direction.
Introduction
In 2010, more than 20,000 people will have been diagnosed with multiple myeloma in the United States. In the past decade, advances in autologous stem cell transplantation and the introduction of thalidomide, bortezomib, and lenalidomide have significantly improved outcomes for myeloma patients [Kumar et al. 2008 ]. However, despite these advances and many decades of research into the nature of the disease, over 10,000 patients with myeloma in the USA still die each year [Jemal et al. 2010] , and the disease remains incurable. Therefore, it is clear that current therapies are still inadequate, and new strategies need to be found.
Multiple myeloma is due to clonal proliferation of malignant plasma cells which affect multiple organ systems in the body. The malignant phenotype of these cells reflects the dysregulation of multiple cell-intrinsic and cell-extrinsic pathways, which leads to disease pathogenesis and can often vary from patient to patient. This results in a spectrum of disease ranging from asymptomatic to life threatening. With better identification of the processes that lead to disease, targeting the molecular abnormalities that cause cellular dysfunction is becoming the goal of future therapeutics. Thus, novel agents are being developed using the knowledge gained from a better understanding of the pathophysiology of myeloma. In this review, we have focused on presenting preliminary safety and efficacy results from early-stage clinical trials using promising novel agents, all of which have strong preclinical rationale for their exploration in myeloma.
Proteasome inhibition
The ubiquitinproteasome system plays a critical role in cellular homeostasis through regulation of protein degradation and turnover. Inhibition of the proteasome leads to accumulation of misfolded or obsolete proteins targeted for destruction, and disrupts the normal signaling pathways regulating cell proliferation and survival. This eventually leads to cell cycle arrest and apoptosis through both the intrinsic and extrinsic apoptotic pathways, although the exact mechanisms involved remain incompletely defined Rajkumar et al. 2005; Adams, 2004] . Proof of the importance of the proteasome for myeloma cell survival was demonstrated by the responses seen in initial clinical studies of the first-in-class proteasome inhibitor bortezomib . Subsequent studies have demonstrated enhanced efficacy of bortezomib when used in combination with steroids, anthracyclines, alkylating agents, and/or immunomodulatory drugs (IMiDs) in both newly diagnosed and relapsed/ refractory myeloma San-Miguel et al. 2008; Orlowski et al. 2007; Jagannath et al. 2005] , and have cemented the place of proteasome inhibition as a current cornerstone of myeloma therapy.
The major toxicity issue with bortezomib is a dose-limiting peripheral neuropathy, which can be severe in 1015% of patients, leads to dose reductions or discontinuation in up to 40%, and may impact both long-term quality of life and the ability to get subsequent therapies [Bringhen et al. 2010; Harousseau et al. 2010; Mateos et al. 2010b; Richardson et al. 2006 ]. One recent approach to mitigate this toxicity has been to administer bortezomib on a weekly schedule, rather than the standard day 1, 4, 8, 11 schedule. Several recent studies of bortezomib-based combinations have demonstrated less neurotoxicity and fewer dose reductions and/or discontinuations when given on days 1, 8, 15, and 22 of a 35-day cycle compared with the standard dosing schedule, with response rates, progression-free survival (PFS), and overall survival (OS) that appear comparable to the standard twice-weekly schedule [Bringhen et al. 2010; Mateos et al. 2010b; Reeder et al. 2010] .
Another approach has been the development of second-generation proteasome inhibitors with different biochemical characteristics than bortezomib. Carfilzomib (PR-171) is a synthetic peptide epoxyketone derived from the natural product epoxomicin, and is structurally distinct from bortezomib, lacking the boronic acid moiety [Bennett and Kirk, 2008] . Like bortezomib, it potently inhibits the chymotryptic-like activity of the b5 subunit of the proteasome, but unlike bortezomib it has minimal effect on the caspase-like activity (subunit b1) and no significant off-target activity against nonproteasomal proteases. In addition, carfilzomib binds irreversibly (unlike bortezomib) to the proteasome, with recovery of cellular proteasomal activity dependent on generation of new proteasomes. Initial in vitro studies demonstrated proteasomal inhibition and induction of apoptosis in multiple tumor cell lines and primary myeloma patient samples, with increased potency compared with bortezomib and activity in some bortezomib-resistant lines. Efficacy was increased with more prolonged exposure to carfilzomib in both in vitro and in vivo models [Demo et al. 2007; Kuhn et al. 2007] .
Initial phase I studies of carfilzomib explored two schedules: daily Â 5 days (repeated every 2 weeks), or daily Â 2 days (repeated weekly for 3 out of 4 weeks). Primary toxicities included myelosuppression, fatigue, and transient creatinine increases, with dose-limiting toxicities (DLT's) of thrombocytopenia and febrile neutropenia. Activity was observed on both schedules, including in some patients with bortezomibrefractory myeloma, and grade 3 or 4 neurotoxicity was seen in less than 1% of patients [O 0 Connor et al. 2009; Stewart et al. 2007 ]. The daily Â 2 days schedule was taken forward into two phase II single-agent trials. In the first study, 266 patients with relapsed and refractory disease (median five prior therapies; prior bortezomib, IMiD, and alkylator required) received carfilzomib at 20 mg/m 2 for the first cycle, and at 27 mg/m 2 for subsequent cycles . A total of 24% of these patients achieved at least a partial response (PR) [0.4% complete response (CR), 4.7% very good partial response (VGPR)] with median duration of response of 7.4 months. An additional 12% achieved minor response (MR) (!25% reduction of M-protein), and 32% achieved stable disease. A second phase II trial in less heavily treated patients (median two prior therapies) showed activity in both bortezomib-treated (ORR 21%, median TTP 8.1 months) and bortezomib-naïve [overall response rate (ORR) 55%, median time to progression (TTP) 11.5 months at the 2027 mg/m 2 dosing schedule] populations. In both of these studies, anemia, thrombocytopenia and neutropenia were the most common grade 3 or higher adverse events, with rare (<1%) incidence of severe peripheral neuropathy. In addition, carfilzomib has been safely combined with lenalidomide and dexamethasone in phase I/II studies in both relapsed/refractory [Bensinger et al. 2010] and newly diagnosed disease [Jakubowiak et al. 2010b] , with promising preliminary efficacy. A phase III trial (ClinicalTrials.gov identifier: NCT01080391) comparing the combination of lenalidomide and dexamethasone with and without carfilzomib is currently recruiting patients with relapsed myeloma. A summary of reported results from clinical trials with carfilzomib is provided in Table 1 . In addition, carfilzomib has been safely given in patients with relapsed/ refractory myeloma with renal insufficiency, including those with a creatinine clearance of less than 30 ml/min . Data on how frequently myeloma-associated renal damage can improve following carfilzomib treatment has not yet been reported.
Another second-generation proteasome inhibitor, salinosporamide (NPI-0052), has a more broad mechanism of action; it not only inhibits chymotryptic activity but also the tryptic-like and caspase-like activity of the proteasome. It is an irreversible inhibitor of the proteasome, and has both oral and intravenous formulations. Like carfilzomib, salinosporamide has significant preclinical activity against myeloma cells, including those from patients with bortezomib-refractory disease [Chauhan et al. 2005] . It also demonstrated in vivo synergistic [Chauhan et al. 2010] effects with lenalidomide at low doses in myeloma cells. The combination was associated with decreased multiple myeloma cell migration and angiogenesis. It also showed increased caspase activity, activation of BH-3 protein Bim, and increased Bim translocation to the endoplasmic reticulum with resultant endoplasmic reticulum stress. Bim increases in response to cell stress, and is important in initiating mitochondrial apoptotic signaling utilizing cytochrome-c release and activation of caspase-9 [Chauhan et al. 2010] . Preliminary results were recently reported from a phase I study of NPI-0052 given intravenously every week for 3 out of 4 weeks in 27 patients with relapsed/refractory myeloma [Richardson et al. 2009b ]. Dose escalation had reached 0.7 mg/m 2 with the maximum tolerated dose (MTD) not yet reached. Toxicities included fatigue, nausea, vomiting, dizziness, diarrhea, headache, and confusion, with no myelosuppression or neuropathy noted. Two minor responses were noted, with eight additional patients achieving stable disease.
Other novel proteasome inhibitors include MLN9708, CEP-18770, and ONX 0912, all of which are orally bioavailable. MLN9708 and CEP-18770 have been shown in preclinical models to be converted into an active agent that reversibly inhibits the chymotrypsin-like proteolytic site of the 20S proteasome [Kupperman et al. 2010; Piva et al. 2008] . ONX 0912 is a tripeptide epoxyketone that is structurally similar to carfilzomib, with equal preclinical potency [Chauhan et al. 2010] . Phase I trials of these oral proteasome inhibitors in patients with myeloma and other relapsed/ refractory tumors are ongoing.
Finally, another novel approach is specific targeting of the immunoproteasome, which is highly expressed in hematopoietic cells, and is involved in peptide processing and presentation on major histocompatibility complex I molecules. Selective inhibition of the immunoproteasome may allow for activity in immune cells while sparing other tissues. In vitro studies ] of a prototypical agent IPSI-001 showed preferential inhibition of the immunoproteasome. It showed activity against many myeloma cell lines including bortezomib-refractory cells. Synergy with dexamethasone was seen as well. However, clinical studies of this or other immunoproteasome inhibitors are not yet underway.
Immunomodulatory drugs
The microenvironment in which myeloma cells reside not only has stimulatory effects on tumor growth, but also induces an immune suppressor response. Interleukin 6 (IL-6), insulinlike growth factor (IGF), vascular endothelial growth factor, tumor necrosis factor-a (TNF-a) along with other cytokines and chemokines contribute to the immune suppression and myeloma progression [Gorgun et al. 2010 ]. Thalidomide and lenalidomide directly kill myeloma cells but also affect the microenvironment and immune response. They enhance natural killer cell function, stimulate T-cell proliferation and CD8 þ Tcell activation, increase IL-2 and interferon-g levels while enhancing the immune response to tumor cells [Gorgun et al. 2010 ].
Pomalidomide (CC-4047) is a second-generation IMiD with more potent immune stimulatory effect and killing of multiple myeloma cells. It suppresses cytokine secretion and has direct antiproliferative and proapoptotic effects on myeloma cells [Hideshima et al. 2000 ]. In addition, CC-4047 inhibited osteoclastogenesis and bone resorption in vitro, suggesting a potential benefit with respect to myeloma-associated lytic bone disease ]. Combinations with proteasome inhibitors have shown increased anti-multiple myeloma effect. In the initial phase I study [Schey et al. 2004] , pomalidomide was given daily with a MTD of 2 mg/day. This showed mostly hematologic toxicities at higher doses, though even at 2 mg/day grade 4 neutropenia was a DLT in two patients. A total of 13 of 24 patients showed a greater than 50% decrease in paraprotein (see Table 2 ). A phase II study of 2 mg of continuous daily pomalidomide, in combination with oral dexamethasone 40 mg once weekly in 60 relapsed patients, demonstrated an overall response rate of 63%, including a 40% response rate in the 20 patients with lenalidomiderefractory disease, and 60% in patients with bortezomib-refractory disease. Grade 3/4 toxicities included neutropenia in 32%, anemia in 5% and thrombocytopenia in 3%. Nonhematologic grade 3/4 toxicities included fatigue and pneumonia in 17% and 8%, respectively. Less than 5% of patients experienced grade 3/4 diarrhea, constipation, hyperglycemia and neuropathy. The median OS had not been reached and the PFS was 11.6 months [Lacy et al. 2009] .
A second phase II study explored this regimen in 34 heavily pretreated patients with lenalidomiderefractory disease [Lacy et al. 2010a] . After a median of five cycles, 11 (34%) of 32 evaluable patients showed at least a partial response, with a duration of response of 9.2 months. Grade 3/4 hematologic toxicities were reported in 53% of patients, and nine patients had grade 1/2 neuropathy. Eight patients with stable disease also had a dose increase to 4 mg/day, and one went on to a PR. Subsequent studies have focused on the bortezomib-and lenalidomide-refractory population, and have found that the pomalidomide dose can be escalated to 4 mg daily, when given on a schedule of 21 out of 28 days, with potentially better tolerability than the continuous schedule Lacy et al. 2010b; Richardson et al. 2010b ]. Preliminary results so far have confirmed a PR or better rates between 26% and 42% in this difficult-to-treat population (Table 2) , with randomized phase 2 studies comparing the two schedules, and exploring the benefit of dexamethasone, currently ongoing (ClinicalTrials.gov identifiers: NCT01053949 and NCT00833833). The safety and efficacy of pomalidomide in patients with significant renal insufficiency (creatinine > 2.5 mg/dl) has not been explored in clinical trials conducted to date.
Histone deacetylase inhibitors
Histone deacetylase (HDAC) inhibitors regulate gene expression by increasing histone acetylation, but in myeloma they also disrupt cellular function through transcriptional upregulation of death receptors, increased oxidative injury and disruption of chaperone protein function [Mitsiades et al. 2003 ]. HDAC inhibitors have demonstrated potent preclinical antimyeloma activity, and appear to synergize with other antimyeloma agents, particularly bortezomib [Campbell et al. 2010; Catley et al. 2006; Pei et al. 2004; Mitsiades et al. 2003 ]. Potential explanations for the synergy include increased apoptosis in cells where bortezomib causes inhibition of nuclear factor-kB, causing disruption of the aggresome and overwhelming the unfolded protein response [Mazumder et al. 2010] . Proteasome inhibition in cells results in accumulation of ubiquitin-conjugated proteins in the perinuclear region as aggresomes, which have a cytoprotective effect. Aggresomes, which require HDAC6 for their formation, are particularly important in proteasome-inhibited malignant cells, and their inhibition enhances bortezomib activity [Nawrocki et al. 2006 ]. Based on this synergy, as well as the fact that single-agent activity in myeloma has been modest [Niesvizky et al. 2011; Richardson et al. 2008; Wolf et al. 2008] , clinical development of the HDAC inhibitors is moving forward in combination with existing agents in myeloma.
The addition of vorinostat (formerly suberoylanilide hydroxamic acid) to bortezomib is associated with antiproliferative and proapoptotic molecular sequelae on myeloma cells, even those resistant to standard or novel therapy [Mitsiades et al. 2003 ]. The combination suppresses growth factor receptors and transcripts, DNA repair enzymes, caspase inhibitors and proteasome subunits. Two phase I studies in 57 patients showed the combination of bortezomib and vorinostat to be well tolerated and demonstrated responses in roughly 40%, including 33% (five of 15) of patients with bortezomib-refractory disease [Badros et al. 2009; Weber et al. 2008 ]. Most common grade 1/2 toxicities were fatigue, diarrhea, nausea, and thrombocytopenia, with one grade 4 thrombocytopenia. A phase II trial is underway looking at the combination of vorinostat with bortezomib in refractory myeloma (ClinicalTrials.gov identifier: NCT00773838), and a phase III trial comparing bortezomib plus vorinostat with bortezomib plus placebo (ClinicalTrials.gov identifier: NCT00773747) in patients with relapsed disease is also enrolling. In these studies, the dosing is 400 mg of vorinostat daily on days 114 of a 21-day cycle, with standard twiceweekly bortezomib administration. The combination of vorinostat, lenalidomide and dexamethasone was found tolerable in 31 heavily pretreated patients with myeloma in a phase I trial [Richardson et al. 2010b] . A total of 87% showed at least stable disease, with two achieving CR, three VGPR and 11 PR. MTD was not reached, with one DLT consisting of grade 3 diarrhea. Grade 3 neutropenia (26%) was the most common toxicity, followed by thrombocytopenia, anemia, diarrhea and fatigue (1016%).
Panobinostat (LBH589) [Mateos et al. 2010] , with grade 3/4 thrombocytopenia in 44%, neutropenia in 37%, eight DLTs (four hematologic, two cardiac, and one each of fatigue and pneumonia), and two deaths from febrile neutropenia that were likely treatment related.
Phospho-inositol-3 kinase/Akt/mTOR inhibitors
The phospho-inositol-3 kinase (PI3K)/Akt pathway is a cascade that is activated by several cytokines or growth factors and mediates proliferation and antiapoptosis. The mammalian target of rapamycin (mTOR) is a downstream target of PI3K/Akt and phosphatase and tensin homolog (PTEN). This pathway is activated in cells exposed to many antimyeloma agents, including bortezomib [Hideshima et al. 2006 ], making it a promising target for combination therapies to overcome resistance to conventional agents. Perifosine is a novel, oral alkyl-phospholipid that inhibits constitutive and IL-6/IGF-1-induced Akt activation in multiple myeloma cells [Hideshima et al. 2006 ]. Akt inhibition leads to cytotoxicity by downregulating survivin, which regulates caspase-3 activity [Hideshima et al. 2007] , and also may have caspaseindependent effects such as increased autophagy and antiangiogenesis [Schmidt-Hieber et al. 2010] .
Perifosine 150 mg daily was studied in a phase II trial [Richardson et al. 2007] in 64 patients with refractory/relapsed multiple myeloma (median four previous therapies, range 111). It had modest activity in this single agent setting, which improved with the addition of dexamethasone to a combined PR plus MR of 38%. Nausea, neutropenia and increased creatinine were observed in 3060% of patients (27% grade 3), with grade 3/4 neutropenia seen in 10 patients.
The combination of perifosine and bortezomib was tested in a phase I/II trial [Richardson et al. 2009c ]. Standard dose bortezomib and perifosine 50 or 100 mg daily were coadministered to heavily pretreated patients, with dexamethasone added on progression. Grade 3/4 anemia, thrombocytopenia, neutropenia, hyponatremia and diarrhea were seen in over 5%, with one grade 3 neuropathy. A total of 82% of the 73 evaluable patients demonstrated stable disease or better (38% MR or better), with median OS in these patients of 33.4 months. A phase I trial investigated perifosine combined with lenalidomide and dexamethasone . A total of 30 patients who had received one to four prior treatments were given 50 or 100 mg of perifosine daily with 15 or 25 mg of lenalidomide (days 121) and 20 mg of dexamethasone (days 14, 912 and 1720 for four cycles, then 20 mg days 14) as part of a 28-day cycle. A total of 50% of the patients showed a partial response or better, and the median OS was 30.6 months. Grade 3/4 adverse events included neutropenia (26%), hypophosphatemia (23%), and thrombocytopenia (16%). A phase III trial is currently comparing the addition of 50 mg perifosine or placebo to dexamethasone and standard dose bortezomib in patients with bortezomib-relapsed (but not refractory) disease (ClinicalTrials.gov identifier: NCT01002248).
Another approach to disrupting the PI3K/Akt pathway is to inhibit the downstream effector molecule, mTOR. A phase II study of the intravenous mTOR inhibitor, temsirolimus (CCI-779) in relapsed and/or refractory multiple myeloma showed PRs in one of 16 patients (plus five MRs) and a median TTP of 4.6 months. A phase I/II study of the combination of 25 mg mg of temsirolimus with weekly bortezomib showed an ORR of 47% in 43 patients in the phase II portion, including 21% (MR or better) in bortezomib-refractory disease. The median TTP was 7.3 months, and no grade 3/4 neuropathy was observed, with cytopenias being the most common grade 3/4 toxicities [Ghobrial et al. 2010 ]. Finally, small molecules that directly inhibit PI3K have been developed and show preclinical activity in myeloma, although clinical data in myeloma are not available to date [McMillin et al. 2009; Harvey and Lonial, 2007] .
Heat shock protein-90 inhibitors Heat shock protein-90 (HSP-90) is a molecular chaperone for proteins that are involved in control of the cell cycle, proliferation and apoptosis. First identified as a class of proteins upregulated in normal cells in response to thermal stress [Ritossa, 1996] , HSPs act by preventing protein aggregation and maintaining the conformation, localization and activity of multiple intracellular proteins, including several involved in oncogenesis (reviewed by Isaacs and colleagues [Isaacs et al. 2003] ). HSP-90 expression is increased in numerous malignant cell types and enhances their ability to resist apoptosis and maintain viability in the face of stressors such as anoxia or chemotherapy (reviewed by Richardson and colleagues [Richardson et al. 2011] ). This makes HSP-90 an attractive target for anticancer therapy Preclinical studies showed that the HSP-90 inhibitor, tanespimycin (KOS-953, 17-AAG), sensitized multiple myeloma cells to bortezomib and inhibited antiapoptotic/proliferative cascades [Mitsiades et al. 2006 ]. This synergy was the basis for combination trials using these agents in myeloma. A phase I/II trial of tanespimycin and bortezomib in 72 relapsed/refractory myeloma patients (median of five prior treatments) showed responses in 48% of bortezomib-naïve patients and 13% of bortezomib-refractory patients [Richardson et al. 2009a ]. The median duration of response (DOR) was 10.7 months, with three patients in PR through 24 months. Interestingly, there was no grade 3/4 neuropathy seen, consistent with preclinical rodent data suggesting that HSP-90 inhibition may have a neuroprotective effect when combined with bortezomib [Flint et al. 2009 ]. A phase III trial (ClinicalTrials.gov identifier: NCT00546780) was comparing bortezomib with and without tanespimycin for patients with myeloma in first relapse. However, that study has been halted by the manufacturer with no further details available. Several new HSP-90 inhibitors, including KW-2478 [Nakashima et al. 2010 ] and NVP-AUY922 [Stuhmer et al. 2008] , have confirmed the preclinical efficacy of HSP-90 inhibition in myeloma cells, and are entering clinical testing.
Monoclonal antibodies
Two broad categories of monoclonal antibodies against myeloma exist: those directly targeting the myeloma cell itself, and those targeting growth and/or survival signals provided by the bone marrow microenvironment.
Targeting myeloma cell surface antigens
Targeting B-cell antigens has yielded excellent results in the hematologic malignancies, with anti-CD20 (rituximab and ofatumumab) and anti-CD52 (alemtuzumab) antibodies being well established agents in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. CD40 is a cell-surface antigen expressed on B cells, and mature B-cell malignancies, including myeloma [Horton et al. 2010; Pellat-Deceunynck et al. 1994] . Two humanized anti-CD40 antibodies have been explored clinically in multiple myeloma: dacetuzumab (SGN-40) is an anti-CD40 antibody with mild agonist activity, and HCD122 (Chr 12.12) is a CD40 antagonist. Despite promising preclinical activity [Tai et al. 2005; Hayashi et al. 2003 ], a phase I trial of SGN-40 in 44 patients with relapsed myeloma showed no objective responses, with stable disease seen in 20% [Hussein et al. 2010] . Common toxicities included grade 1 fatigue (57%), transient elevated transaminases (41%, 9% of which were grade 2/3), ocular inflammation (16%) and a cytokine release syndrome (41% with first dose), which was mitigated with preinfusion steroids. HCD122 similarly showed minimal singleagent activity in myeloma [Bensinger et al. 2006 ]. Current strategies involving anti-CD40 antibodies include combination approaches with lenalidomide and dexamethasone [Agura et al. 2009 ], and antibody re-engineering to enhance FcgR binding in order to augment antibody-dependent cellular cytoxicity [Horton et al. 2010] , which may improve efficacy of this approach in future clinical studies.
CD56 is expressed on 80% of myeloma cells and is associated with the upregulation of the SOX4 Therapeutic Advances in Hematology 2 (4) family of transcription factors, which is important in early B-cell and late T-cell development [Iqbal et al. 2010] . Lorvotuzumab mertansine (IMGN901, BB-10901) is an antibody conjugate consisting of DM1 bound to a humanized anti-CD56 antibody. DM1 (mertansine) is a cytotoxic maytansinoid that can be conjugated via disulfide linkages to an antibody against a specific target. Maytansinoids are potent compounds that target microtubules and cause mitotic arrest [Lopus et al. 2010] . The combination binds to CD56 and the antibodymaytansinoid complex is internalized, releasing the active metabolite within the myeloma cell resulting in cell death. The specific targeting avoids the severe side effects that limit the systemic use of DM1 [Erickson et al. 2006; Cassady et al. 2004; Tassone et al. 2004] . As a monotherapy, lorvotuzumab induced responses in five of 28 evaluable patients in a phase I study, with an MTD of 112 mg/m 2 per week and four grade 3 toxicities of headache, neuropathy, transaminitis, hyperuricemia, and fatigue seen in three patients [Chanan-Khan et al. 2010] . A phase I combination trial with lenalidomide and dexamethasone is ongoing (ClinicalTrials.gov identifier: NCT00991562).
Elotuzumab is a monoclonal antibody targeting the cell surface glycoprotein CS1. While not expressed in most normal tissue or stem cells, CS1 is found in high levels on myeloma cells regardless of cytogenetic abnormalities [Hsi et al. 2008] . A phase I monotherapy trial showed good tolerability with no MTD reached, but minimal single-agent activity. The primary toxicity was infusion-related reactions [Zonder et al. 2008] . Phase I/II trials showed elotuzumab to be tolerable in combination with full doses of bortezomib or lenalidomide and dexamethasone [Lonial et al. 2010; Jakubowiak et al. 2010a] in patients with previously treated myeloma. In a phase II study, lenalidomide-naïve patients with multiple myeloma who had received one to three prior therapies received 10 or 20 mg/kg of elotuzumab in combination with lenalidomide and dexamethasone . For the first 28-day cycle, elotuzumab was given weekly, then every 2 weeks for subsequent cycles. Responses were seen in 22/26 (85%) patients (one CR, seven VGPRs and 14 PRs), and serious adverse events were seen in 22%. These included infusion-related reactions (dizziness 15%, nausea 15%, headache 9%) which were ameliorated by augmented premedication with steroids and histamine blockers. Phase III trials comparing lenalidomide and dexamethasone with and without elotuzumab for both relapsed and newly diagnosed myeloma are expected to begin in 2011 (ClinicalTrials.gov identifier: NCT01239797).
Several additional antibodies targeting myeloma surface antigens have entered clinical development, including milatuzumab (anti-CD74) [Kaufman et al. 2009 ], daratumumab (anti-CD38) [Kong et al. 2010] and BT062 (an anti-CD138-DM4 conjugate) , further expanding the pool of candidate therapeutic antibodies with potential utility in myeloma.
Targeting the myeloma microenvironment Myeloma has complex and dependent interactions with the microenvironment in which the malignant cells reside. Multiple factors within the bone marrow provide protective signals to myeloma cells, contributing to cell survival and drug resistance. IL-6 is one such factor and normally plays important roles in bone metabolism. In myeloma, it is produced primarily by bone marrow stromal cells and can enhance the growth and survival of myeloma cells. IL-6 receptor binding induces phosphorylation of gp130. This results in activation of three major signaling cascades: Ras/Raf/MEK/ERK, JAK-2/STAT3, and Pi3K/Akt, all of which combine to promote myeloma cell proliferation, survival and drug resistance [Yasui et al. 2006 ]. A phase I study using a first-generation chimeric anti-IL-6 antibody as a single agent showed limited activity in relapsed/refractory myeloma [van Zaanen et al. 1998 ].
A newer high-affinity chimeric anti-IL-6 antibody, CNTO 328, was shown to potentiate apoptosis in the presence of dexamethasone by increased caspase activation and DNA fragmentation ], and also synergistically increased susceptibility of myeloma cells to bortezomib-induced cell death . CNTO 328 (siltuximab) did show single-agent clinical activity in a phase I trial in relapsed/refractory lymphoma, myeloma, and Castleman's disease [Kurzrock et al. 2008] . Commonly observed toxicities were generally mild and included upper respiratory or urinary infections, myelosuppression, elevated ALT, hypertriglyceridemia, diarrhea, nausea, fatigue, and headache, with no dose-limiting toxicity identified in 52 patients. Ongoing studies in combination with dexamethasone, melphalan, and/or bortezomib (ClinicalTrials.gov identifiers: NCT00911859 and NCT01266811) should help define the activity of this agent as an adjunct to currently used therapies in myeloma.
B-cell activating factor (BAFF) is a TNF superfamily member that can cause activation of nuclear factor kB by classical and alternative pathways, leading to expansion of the B-cell compartment and extended B-cell survival [Baud and Karin, 2009] . BAFF also plays a role in B-cell maturation and immunoglobulin secretion [Zheng et al. 2005] , and is overexpressed in the serum and bone marrow environment in myeloma, where it can provide a survival signal to myeloma cells [Tai et al. 2006 ]. This has made it a rational target in myeloma. A neutralizing anti-BAFF antibody demonstrated significant activity in a myeloma xenograft model [Neri et al. 2007] , and LY2127399, a human IgG4 antibody against BAFF, is currently in a phase I trial in combination with bortezomib in relapsed myeloma (ClinicalTrials.gov identifier: NCT00689507).
IGF-1 receptor (IGF-1R) is expressed on myeloma cells, with higher expression in patients with myeloma with one of the translocations associated with poor prognosis, t(4;14) and t(14;16), making it an attractive target for therapy [Bataille et al. 2005] . IGF-1 is produced by myeloma cells as part of an autocrine loop promoting proliferation and survival, as well as by osteoclasts in the bone marrow, and separately confers a poor prognosis in addition to its association with high risk translocations [Sprynski et al. 2009 ]. Monoclonal antibodies against IGF-1R have had disappointing clinical results as monotherapy in myeloma [Lacy et al. 2007; Moreau et al. 2007 ]. However, small molecule IGF-1R tyrosine kinase inhibitors (e.g. NVP-AEW541, BMS-754807) have shown activity in vitro against myeloma [Carboni et al. 2009; Maiso et al. 2008] , and are entering early clinical development.
Other novel agents

Cell cycle and mitotic inhibitors
Cell cycle dysregulation is a common event in malignant plasma cells, with overexpression of cyclin D proteins seen in the majority of myeloma patients [Bergsagel et al. 2005 ]. Inhibition of cyclin-dependent kinases (CDKs) induces cellcycle arrest in myeloma cells and sensitizes cells to dexamethasone-or bortezomib-induced apoptosis [Menu et al. 2008; Baughn et al. 2006 ]. In a phase I trial in combination with bortezomib, the CDK 4/6 inhibitor PD 0332991 was shown to reversibly induce cell cycle arrest in patient myeloma cells, and could feasibly be given with bortezomib, with grade 3 thrombocytopenia and neutropenia as the most common toxicities. A phase II study of this combination is ongoing [Niesvizky et al. 2010 ].
Inhibitors of aurora kinases and kinesin spindle proteins, two classes of proteins involved in regulating mitotic progression, have shown promising preclinical activity against myeloma cell lines and primary myeloma patient samples, with induction of mitotic arrest and blockade of cellular proliferation [Tunquist et al. 2010; Hose et al. 2009; Shi et al. 2007] . A phase I study of MLN8237, an oral aurora-A kinase inhibitor, in relapsed/refractory hematologic malignancies found the MTD to be 45 mg daily for 14 out of 28 days, with thrombocytopenia (36%), neutropenia (46%), and asthenia (32%) as the most common toxicities of all grades, with myelosuppression as the DLT [Padmanabhan et al. 2010] . Expansion of the MTD in this study, as well as a separate phase I trial evaluating the combination of MLN 8237 and bortezomib in patients with myeloma, are ongoing. A phase I trial of ARRY-520, an intravenous kinesin spindle protein inhibitor, in relapsed/refractory myeloma (median five prior therapies) found the MTD to be 1.5 mg/m 2 on days 1, 2 every 14 days. Dose-limiting toxicity was febrile neutropenia, which was ameliorated by adding filgrastim with each cycle, and mucositis. Ten of 23 evaluable patients (43%) achieved stable disease or better, and phase II dose expansion is ongoing [Shah et al. 2010] .
Plitidepsin
Plitidepsin is an antitumor agent derived from the marine tunicate Aplidium albicans that activates p38 pathways and Jun N-terminal kinase signaling . It is also involved in caspase activation and Fas/CD95 translocation to lipid rafts, and can induce myeloma cell apoptosis in vitro even in the presence of protective bone marrow stromal cells. In a phase II study plitidepsin was administered to 51 heavily pretreated patients with myeloma [Mateos et al. 2010b ]. The most common grade 3/4 toxicities were anemia (29%), thrombocytopenia (18%), creatine phosphokinase (CPK) elevation (14%), ALT elevation (28%), and fatigue (16%). Singleagent activity was observed, with an ORR (MR or better) of 13%, which improved to 22% with the addition of dexamethasone. A phase III study of plitidepsin plus dexamethasone versus dexamethasone alone in patients whose disease relapsed after three to six prior therapies (including bortezomib and an IMiD) is currently recruiting (ClinicalTrials.gov identifier: NCT01102426).
Targeting the myeloma stem cell Much attention in anticancer therapy has recently been focused on stem cells as perhaps the 'holy grail' of eradicating disease. This is of particular interest in myeloma as immunoglobulin gene rearrangement and idiotype provide a method for assessing clonal relationships [Ghosh and Matsui, 2009] . Myeloma plasma cells that express CD138 have been shown to have limited clonogenic potential, whereas CD138 cells are much fewer in number and do have clonogenic potential, suggesting stem cell-like properties [Brennan and Matsui, 2009 ]. These cells with clonogenic potential also express CD45, CD19, CD20, and CD22. Although their numbers are small, these phenotypic B cells with clonogenic potential do demonstrate relative resistance to many antimyeloma therapies. CD138 cells demonstrated less responsiveness to glucocorticoids, lenalidomide, bortezomib, and alkylating agents than CD138 þ cells [Matsui et al. 2008 ].
In addition, targeting CD138 cells presents other challenges. They have complex interactions with their microenvironment, including growth regulation via the Hedgehog pathway [Peacock et al. 2007 ]. This pathway can be activated by Hedgehog ligands that are secreted in both a paracrine and autocrine manner. These bind to the transmembrane receptor called Patched (Ptch1), which leads to loss of repression of Smoothened (Smo) . This results in modulation of the transcription factor Gli, which in turn leads to transcription of target genes [Matsui et al. 2008] . Activation of the Hedgehog pathway resulted in cancer stem cell self-renewal and expansion, while inhibition induced terminal differentiation and loss of clonogenic growth potential [Matsui et al. 2008] . In mouse models, Hedgehog inhibition by cyclopamine combined with inhibition of the Wnt signaling pathway resulted in significantly reduced tumor burden and prolonged survival [Tricot et al. 2010] .
The Hedgehog pathway inhibitor BMS-833923 is currently undergoing phase I trials in patients with myeloma with bortezomib, lenalidomide/ dexamethasone and as a single agent.
The ability of stem cells to remain quiescent and the drug transporters they possess make them particularly difficult targets. In addition, there remains controversy over the exact nature and phenotype (and some would argue, existence) of the myeloma stem cell, and the discovery that some CD34 þ CD138 þ myeloma cells also have the ability to grow independently [Kuranda et al. 2010] indicates that our understanding of stem cells in myeloma needs to expand. However, as new pathways are identified, agents directed against clonogenic myeloma cells may eventually play as important a role as treatment against differentiated plasma cells.
Rituximab
Because clonogenic precursors in myeloma have been reported to express B-cell antigens, such as CD20, and because 1015% of patients with myeloma will have some level of CD20 expression on their CD138 þ mature plasma cells [Robillard et al. 2003 ], rituximab has been explored as an antimyeloma therapy. It has shown in vitro ability to cause antibodydependent cellular lysis and limit tumor growth [Matsui et al. 2008] . The literature on rituximab use in patients with myeloma consists largely of case series and small trials, with relatively disappointing results [Kapoor et al. 2008 ]. In the largest prospective study reported [Treon et al. 2002] , five out of 19 previously treated patients showed stable disease, with one showing PR to rituximab. Only patients with CD20 þ plasma cells showed any clinical benefit, a pattern seen in most of the other reported studies as well [Kapoor et al. 2008 ]. Thus, so far, the notion that clonogenic myeloma precursors can be eliminated through targeting CD20 þ cells has yet to be borne out clinically.
Summary/future directions Antimyeloma therapy represents an exciting field in hematology. When thalidomide was noted to have single-agent activity against myeloma in 1999, it was the first new agent to do so in more than 30 years [Singhal et al. 1999 ]. Since then, great strides have been made in slowing down disease mortality, but clearly more is needed. We know much more about myeloma, and further breakthroughs are more likely to come from rational targeting of the disease than the fortuitous rediscovery of older drugs. Targeting the differentiated disease-causing cells in myeloma has yielded significant results and will remain the main focus of experimental therapy, though attempts to identify and target the myeloma stem cell continue, with the goal of inducing durable and perhaps even permanent responses. Identifying resistance mechanisms and better administration methods have allowed us to use existing agents for longer and in more powerful combinations. The isolation of accessory pathways that gain prominence in myeloma cells exposed to existing drugs have led to novel agent combinations that disrupt these pathways and overcome resistance. Finally, even as new versions of existing agents with less toxicity are identified and replace the old standards, entirely new classes are demonstrating activity in earlystage clinical trials. These developments give hope that the newer myeloma treatments will be even more efficacious and better tolerated than the breakthrough agents of the last decade. Gorgun, G., Calabrese, E., Soydan, E., Hideshima, T., Perrone, G., Bandi, M. et al. (2010) Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116: 32273237.
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